Comments
Loading...

Allogene Therapeutics

ALLONASDAQ
Logo brought to you by Benzinga Data
$3.00
0.124.17%
Last update: 9:07 AM
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$31.00
Lowest Price Target1
$4.60
Consensus Price Target1
$13.42

Allogene Therapeutics (NASDAQ:ALLO) Stock, Analyst Ratings, Price Targets, Forecasts

Allogene Therapeutics Inc has a consensus price target of $13.42 based on the ratings of 21 analysts. The high is $31 issued by Goldman Sachs on March 2, 2023. The low is $4.6 issued by Stifel on May 14, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Citigroup, and Truist Securities on August 15, 2024, August 9, 2024, and August 9, 2024, respectively. With an average price target of $10.33 between HC Wainwright & Co., Citigroup, and Truist Securities, there's an implied 244.44% upside for Allogene Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
May
1
Aug
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Citigroup
Truist Securities
Oppenheimer
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for Allogene Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Allogene Therapeutics (ALLO) stock?

A

The latest price target for Allogene Therapeutics (NASDAQ:ALLO) was reported by HC Wainwright & Co. on August 15, 2024. The analyst firm set a price target for $9.00 expecting ALLO to rise to within 12 months (a possible 200.00% upside). 19 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Allogene Therapeutics (ALLO)?

A

The latest analyst rating for Allogene Therapeutics (NASDAQ:ALLO) was provided by HC Wainwright & Co., and Allogene Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Allogene Therapeutics (ALLO)?

A

The last upgrade for Allogene Therapeutics Inc happened on January 24, 2023 when JP Morgan raised their price target to $11. JP Morgan previously had a neutral for Allogene Therapeutics Inc.

Q

When was the last downgrade for Allogene Therapeutics (ALLO)?

A

The last downgrade for Allogene Therapeutics Inc happened on January 5, 2024 when Guggenheim changed their price target from N/A to N/A for Allogene Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.

Q

Is the Analyst Rating Allogene Therapeutics (ALLO) correct?

A

While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a reiterated with a price target of $9.00 to $9.00. The current price Allogene Therapeutics (ALLO) is trading at is $3.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch